BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37260331)

  • 1. The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.
    Chen X; Bai X; Xie X; Huang J; Chen L; Song L; Lan X; Zhang Q; Guo J; Du C
    Ann Med; 2023 Dec; 55(1):2218647. PubMed ID: 37260331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
    Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
    Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
    BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
    Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
    Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
    Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Tan A; Nong L; Wang H; Jia Y; Zhong W; Qin F; Wang H; Tang J; Liu Y; Lu Y
    Cancer Biol Ther; 2023 Dec; 24(1):2265055. PubMed ID: 37831547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Leone JP; Duda DG; Hu J; Barry WT; Trippa L; Gerstner ER; Jain RK; Tan S; Lawler E; Winer EP; Lin NU; Tolaney SM
    Breast Cancer Res Treat; 2020 Jan; 179(1):113-123. PubMed ID: 31541381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
    Shawky H; Tawfik H
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
    Hulsbergen AFC; Cho LD; Mammi M; Lamba N; Smith TR; Brastianos PK; Broekman MLD; Lin NU
    Breast Cancer Res Treat; 2020 Feb; 180(1):147-155. PubMed ID: 31953697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
    Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
    Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
    Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
    Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
    Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    Zeng T; Sun C; Liang Y; Yang F; Yan X; Bao S; Zhang Y; Huang X; Fu Z; Li W; Yin Y
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
    Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
    J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.